Biogen (BIIB) Tops Q3 EPS by 71c, Updates Guidance, Approves $5 Billion Buyback

(Updated - October 21, 2020 7:06 AM EDT)

Biogen (NASDAQ: BIIB) reported Q3 EPS of $8.84, $0.71 better than the analyst estimate of $8.13. Revenue for the quarter came in at $3.38 billion versus the consensus estimate of $3.35 billion.

GUIDANCE:

Biogen sees FY2020 EPS of $32.50-$33.50, versus the consensus of $34.77.

• Company announces new $5.0 billion share repurchase authorization

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Bassett Furniture Industries (BSET) Tops Q2 EPS by 1c, Misses on Revenue
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance